Novavax, (NVAX) Climbs 9.28% on May 13

Equities Staff  |

Novavax, Inc. (NASDAQ: NVAX) has risen $4.45 (9.28%) and sits at $52.24, as of 12:05:07 est on May 13.

3,648,330 shares exchanged hands.

The Company fell 18.21% over the last 5 days and shares have fallen 17.42% over the last 30 days.

Novavax, expects its next earnings on 2022-08-08.

For technical charts, analysis, and more on Novavax, visit the company profile.

About Novavax, Inc.

Novavax, Inc. is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

To get more information on Novavax, Inc. and to follow the company's latest updates, you can visit the company's profile page here: Novavax, Inc.'s Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Big Lots Down 18% in Premarket Trading Friday on Surprise Missed Earnings
Modine Posts Strong Rebound in Fiscal Q4, Raises 2023 Guidance
Dollar Tree Posts Record First Quarter, Leads Nasdaq Gainers
Kohl's Still in Play To Be Acquired
Chinook Therapeutics Raises $105 Million for Kidney Disease Therapies
Market Conditions Driving Higher Base Level for VIX Volatility Index
Will New AT&T, Dish Co-opetition Deal Work: Jeff Kagan
Cisco Down 12% in Premarket Trading Thursday After Top Line Miss and Lower Forecast



Market Movers

Sponsored Financial Content